Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.
Gross profit for 2024 dropped to $0.5 million ... previously expensed to research and development expenses prior to FDA approval of the 365-day product. Fourth quarter 2024 selling, general ...
ANI Pharmaceuticals (ANIP) announced that the U.S. FDA has approved an expanded label for Iluvien that includes an indication for the treatment ...
Q4 2024 Earnings Call Transcript March 12, 2025 InspireMD, Inc. beats earnings expectations. Reported EPS is $-0.18, ...
Dr. Dennis Gross’ SpectraLite FaceWare Pro mask stood out to me because it looked like something Beyoncé would’ve worn on her Renaissance tour—and it's FDA-approved to treat acne and ...
The gross margin improved significantly from 25% in the fourth quarter of 2023 to 37% in the fourth quarter of 2024. This expansion in profitability helped ImmuCell swing to a net income of $ ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results